IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1268
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$3.5B
Mary A. Heino
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates disease burden of prostate cancer by quantifying the hotspots on bone scans.
Headcount
700
HQ Base
NORTH BILLERICA, Massachusetts
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = LNTH ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$LNTH Lantheus Holdings, Inc. | 55 | 60 | 58 | 48 | 15.8x | 13.3x | 27.8% | 13.6% | 62.3% | 24.3% | 20.6% | -2.6% | 0.0% | 103.0x | $3.5B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Lantheus Holdings, Inc. (LNTH) receives a "Hold" rating with a composite score of 55.0/100. It ranks #1268 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Fair valuation relative to peers
High profitability & efficiency — strong quality floor supports entry
Low volatility — smoother ride and historically better risk-adjusted returns
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for LNTH.
View All RatingsROIC 14.5% vs WACC 8.8% (spread +5.7%)
GM 62% vs sector 44%, OM 24% vs sector 3%
Capital turnover 2.06x, R&D intensity 11.4%
Rev growth -3%, 10yr history
Interest coverage 8.8x, Net debt/EBITDA 4.3x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Lantheus Holdings, Inc. (LNTH) as a Hold with a composite score of 55.0/100 at a current price of $74.00. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
Lantheus Holdings, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 55.0/100 places it at rank #1268 in our full universe.
Narrow
Medium
Standard
Fair Value
Gross margins of 62% signal strong pricing power.
Returns on equity of 27.8% exceed cost of capital.
Stable competitive position in a defensive sector.
Leverage of 103% D/E amplifies downside risk.
Vulnerability to macroeconomic shocks and interest rate volatility.
Lantheus Holdings, Inc. represents a hold based on multi-factor quantitative performance.
Our model assigns Lantheus Holdings, Inc. a Hold rating, with a composite score of 55.0/100 and 3 out of 5 stars. Ranked #1268 of 7,333 stocks, LNTH presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 60/100, LNTH shows adequate but unremarkable business quality. The company reports a return on equity of 27.8% (sector avg: -1.9%), gross margins of 62.3% (sector avg: 44.1%), net margins of 20.6% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
LNTH's value score of 58/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 15.77x, an EV/EBITDA of 13.33x, a P/B ratio of 4.38x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
Lantheus Holdings, Inc.'s investment score of 29/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -2.6% vs. a sector average of 6.7% and a return on assets of 13.6% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
LNTH is currently showing below-average momentum at 48/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at -2.6% year-over-year, while a beta of 0.46 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
LNTH shows good financial stability with a score of 70/100. Key stability metrics include a beta of 0.46 and a debt-to-equity ratio of 103.00x (sector avg: 0.2x). This suggests manageable leverage and moderate price volatility, making it appropriate for investors seeking a balance between growth potential and capital preservation.
The short interest score of 43/100 for LNTH suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 103.00x). With a $3.5B market cap (mid-cap), Lantheus Holdings, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Lantheus Holdings, Inc. is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1268 of 7,333 overall (83rd percentile). Key comparisons include ROE of 27.8% exceeding the -1.9% sector median and operating margins of 24.3% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While LNTH currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Stability (70) vs Investment (29) — closing this gap could shift the rating.
EV/EBITDA 16% ABOVE SECTOR MEDIAN
ROE 1561% BELOW SECTOR MEDIAN
Gross Margin 41% ABOVE SECTOR MEDIAN (FAVORABLE)
Above 50MA
37.18%
Net New Highs
+51081
The healthcare sector is divided. We analyze 10 high-conviction small-cap opportunities with 30-50% upside, featuring Viking Therapeutics and Hims & Hers.
Nitorum Capital fully exited its stake in Lantheus Holdings, selling 344,444 shares worth $28.2 million in Q3. The exit comes as Lantheus faces significant headwinds including a 77% year-over-year earnings decline, declining sales of its flagship prostate cancer imaging agent, CEO retirement, and margin compression despite strong revenue generation.
Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) will be reporting earnings this Thursday before the bell. Here’s what to expect.
BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced Mary Anne Heino, Executive Chairperson and Chief Executive Officer, will present at the following investor conferences. TD Cowen 46th Annual Health Care ConferenceMarch 3, 2026 at 11:10 a.m. ETLeerink Global Healthca
Kahn Swick & Foti, LLC recently opened an investigation into Lantheus Holdings over revenue weakness and lowered guidance for its key imaging agent Pylarify, alongside existing securities litigation focused on alleged disclosure issues. This mix of legal scrutiny and concerns about forecasting reliability directly challenges how investors assess the quality of management’s decisions and future visibility. We’ll now examine how the Pylarify-related investigation and disclosure concerns could...